Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for the underlying cancer
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mortality of cancer patients under active anticancer treatment | Mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative). | 28 days after the date of the diagnostic procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival will be defined as the time from the date of the first diagnostic procedure (either diagnostic test or chest imaging) to the date of death due to any cause. | 6 months (i.e. at the the time of last patient last visit) |
| Hospitalizations |
Not provided
Inclusion Criteria:
I1. Confirmed diagnosis of any type of solid or hematologic tumor;
I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ;
I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (>38°C) and/or respiratory tract symptoms), either confirmed or not.
Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ;
I4. Patient and/or family did not decline data collection after complete information.
Not provided
Not provided
Not provided
Not provided
Patients with cancer in active phase of treatment suspected or diagnosed of a SARS-CoV-2 infection
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Bergonié | Bordeaux | France | ||||
| Centre François Baclesse |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34135471 | Derived | Assaad S, Zrounba P, Cropet C; ONCOVID-19 study Consortium; Blay JY. Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. Br J Cancer. 2021 Aug;125(5):658-671. doi: 10.1038/s41416-021-01452-4. Epub 2021 Jun 16. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients) |
| 28 days after the date of the diagnostic procedure |
| Death | Cause of death, related or not to the COVID-19 | 6 months (i.e. at the the time of last patient last visit) |
| Complications | Associated complications described by their type | 28 days after the date of the diagnostic procedure |
| Hospitalizations | proportion of hospitalizations | 28 days after the date of the diagnostic procedure |
| Patients' characteristics | To describe accurately patients' characteristics in terms of demographics | At the date of the diagnostic procedure |
| Patients' characteristics | To describe accurately patients' characteristics in type of tumor | At the date of the diagnostic procedure |
| Patients' characteristics | To describe accurately patients' characteristics in type of anticancer treatment, | At the date of the diagnostic procedure |
| Patients' characteristics | To describe accurately patients' characteristics in terms of comorbidities | At the date of the diagnostic procedure |
| Caen |
| 14076 |
| France |
| Centre Hospitalier Métropole Savoie | Chambéry | 73011 | France |
| Centre Jean Perrin | Clermont-Ferrand | 63011 | France |
| Centre Georges François Leclerc | Dijon | 21079 | France |
| Centre Oscar Lambret | Lille | 59020 | France |
| Centre Leon Berard | Lyon | 69373 | France |
| CH Annecy-Genevois | Metz-Tessy | 74370 | France |
| Groupement Hospitalier Porte de Provence | Montélimar | 26216 | France |
| Institut de Cancérologie de Montpellier | Montpellier | 34298 | France |
| Centre Antoine Lacassagne | Nice | France |
| Centre Hospitalier Lyon-Sud | Pierre-Bénite | 69495 | France |
| Institut Jean Godinot | Reims | 51726 | France |
| Centre Henri Becquerel | Rouen | 76038 | France |
| Institut de Cancérologie de l'Ouest | Saint-Herblain | 44805 | France |
| Institut de cancérologie Strasbourg Europe (ICANS) | Strasbourg | 67033 | France |
| Institut Universitaire du Cancer de Toulouse - IUCT Oncopole | Toulouse | 31059 | France |
| CH Valence | Valence | France |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided